Astrazeneca Ab

Cathy Dantzman

Bernard Christophe Barlaam

Glen E Ernst

Megan Murphy King

Peter Robert Bernstein

Keith John Herzog

Thomas Hudzik

Paul Warwick

Khanh Bui

Russell Bialecki

Glen Ernst

Jingbo Yan

Jie Liu

Valerie Hoesch

N-(2-hydroxyethyl)-N-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide, pharmaceutically acceptable salts thereof, and/or mixtures thereof, as well as, pharmaceutical compositions thereof, methods of treatment therewith, and processes of making N-(2-hydroxyethyl)-N-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide and intermediates thereof.

N-(2-hydroxyethyl)-N-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl

N-(2-hydroxyethyl)-N-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide

NK2R binding compounds in accord with structural diagram I useful for the treatment or prevention of OAB or UI in mammals, particularly humans are disclosed: wherein in said compounds D, A, R, Rand Rare as defined in the specification. Pharmaceutically-advantageous salts of the compounds, methods of use of the compounds, either alone or in combination with other pharmacological agents, and pharmaceutical compositions useful in practicing the methods of the invention are also disclosed.

Compounds and method for the treatment of overactive bladder

Compounds of the following formula (I) wherein RR, n, Arand Aare as defined in the specification, in vivo-hydrolysable precursors thereof, pharmaceutically acceptable salts thereof, the use in therapy and pharmaceutical compositions and methods of treatment using the same. The example compounds are 1-(2-(naphthylmethoxy)-1-phenylethyl)piperazine derivatives. The compounds are neurokinin 1 (NK) receptor antagonist and/or serotonin reuptake inhibitors, with medical indications for depression and other disorders 

[object Object]

The invention relates to novel compounds having the general formula: (I) and arc useful as selective ER-&#x3b2; ligands in the treatment or prophylaxis of Alzheimer's disease, anxiety disorders, depressive disorders, osteoporosis cardiovascular disease, rheumatoid arthritis or prostate cancer.

Selective estrogen receptor-&#x3b2; ligands

Compounds of the formula (I) for use as an estrogen receptor-&#x3b2;-selective ligand are described wherein: X is O or S; and R, RRare as described in the specification. The use of these compounds in treating Alzheimer's disease, anxiety disorders, depressive disorders, osteoporosis, cardiovascular disease, rheumatoid arthritis and prostate cancer is described; as are processes for making them.

Therapeutic benzoxazole compounds

Growing community of inventors

Wilmington, DE, United States of America

Cathy Dantzman